rosuvastatin calcium + atorvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndromes
Conditions
Acute Coronary Syndromes
Trial Timeline
Dec 1, 2003 → Aug 1, 2007
NCT ID
NCT00214630About rosuvastatin calcium + atorvastatin
rosuvastatin calcium + atorvastatin is a phase 3 stage product being developed by AstraZeneca for Acute Coronary Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT00214630. Target conditions include Acute Coronary Syndromes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00214630 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Coronary Syndromes